• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

To escalate thromboprophylacic heparin intensity in COVID-19 or not? That is still the question.

作者信息

Bikdeli Behnood

机构信息

Cardiovascular Medicine Division Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA.

Thrombosis Research Group Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA.

出版信息

Res Pract Thromb Haemost. 2022 May 29;6(4):e12738. doi: 10.1002/rth2.12738. eCollection 2022 May.

DOI:10.1002/rth2.12738
PMID:35664534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9148841/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93aa/9148841/7c57ceb35edd/RTH2-6-e12738-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93aa/9148841/7c57ceb35edd/RTH2-6-e12738-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93aa/9148841/7c57ceb35edd/RTH2-6-e12738-g001.jpg

相似文献

1
To escalate thromboprophylacic heparin intensity in COVID-19 or not? That is still the question.在新冠肺炎患者中是否增加预防性抗凝肝素的剂量？这仍然是个问题。
Res Pract Thromb Haemost. 2022 May 29;6(4):e12738. doi: 10.1002/rth2.12738. eCollection 2022 May.
2
The Value of Thromboelastography (TEG) in COVID-19 Critical Illness as Illustrated by a Case Series.血栓弹力描记术（TEG）在 COVID-19 危重症中的价值：病例系列说明。
J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt A):2536-2543. doi: 10.1053/j.jvca.2021.10.015. Epub 2021 Oct 16.
3
Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature.狼疮抗凝物是否为 COVID-19 的重要特征？文献评价。
Semin Thromb Hemost. 2022 Feb;48(1):55-71. doi: 10.1055/s-0041-1729856. Epub 2021 Jun 15.
4
The association between treatment with heparin and survival in patients with Covid-19.肝素治疗与 COVID-19 患者生存之间的关联。
J Thromb Thrombolysis. 2020 Aug;50(2):298-301. doi: 10.1007/s11239-020-02162-z.
5
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
6
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.COVID-19 患者的抗凝治疗：鸟瞰。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.
7
Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.皮下缓慢注射肝素与快速注射肝素预防瘀斑和注射部位疼痛强度的比较。
Cochrane Database Syst Rev. 2021 Jun 8;6(6):CD008077. doi: 10.1002/14651858.CD008077.pub6.
8
The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19.肝素诱导的血小板减少症和血小板因子 4 抗体与 COVID-19 的复杂关系。
Int J Lab Hematol. 2021 Aug;43(4):547-558. doi: 10.1111/ijlh.13582. Epub 2021 May 17.
9
Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.皮下注射肝素时慢速与快速注射对预防瘀伤及注射部位疼痛强度的影响
Cochrane Database Syst Rev. 2017 Oct 1;10(10):CD008077. doi: 10.1002/14651858.CD008077.pub4.
10
Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.皮下注射肝素时慢速与快速注射对预防瘀伤及注射部位疼痛强度的影响
Cochrane Database Syst Rev. 2017 Nov 1;11(11):CD008077. doi: 10.1002/14651858.CD008077.pub5.

引用本文的文献

1
Closer to FREEDOM From Uncertainty.离摆脱不确定性的自由更近一步。
J Am Coll Cardiol. 2023 May 9;81(18):1763-1765. doi: 10.1016/j.jacc.2023.03.407.

本文引用的文献

1
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial.治疗性抗凝预防重症新型冠状病毒肺炎血栓形成、凝血病及死亡：瑞士COVID-HEP随机临床试验
Res Pract Thromb Haemost. 2022 May 18;6(4):e12712. doi: 10.1002/rth2.12712. eCollection 2022 May.
2
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.COVID-19 患者的抗凝治疗：JACC 本周专题评论
J Am Coll Cardiol. 2022 Mar 8;79(9):917-928. doi: 10.1016/j.jacc.2021.12.023.
3
Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report.
COVID-19 患者的血栓预防：对 CHEST 指南和专家小组报告的简要更新。
Chest. 2022 Jul;162(1):213-225. doi: 10.1016/j.chest.2022.02.006. Epub 2022 Feb 12.
4
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.非危重症 COVID-19 住院患者中 P2Y12 抑制剂对无器官支持生存的影响：一项随机临床试验。
JAMA. 2022 Jan 18;327(3):227-236. doi: 10.1001/jama.2021.23605.
5
Randomized trials of therapeutic heparin for COVID-19: A meta-analysis.COVID-19治疗性肝素的随机试验：一项荟萃分析。
Res Pract Thromb Haemost. 2021 Dec 17;5(8):e12638. doi: 10.1002/rth2.12638. eCollection 2021 Dec.
6
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.利伐沙班与 COVID-19 住院后出院后抗栓预防（MICHELLE）：一项开放标签、多中心、随机、对照试验。
Lancet. 2022 Jan 1;399(10319):50-59. doi: 10.1016/S0140-6736(21)02392-8. Epub 2021 Dec 15.
7
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 患者住院期间使用阿司匹林（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Jan 8;399(10320):143-151. doi: 10.1016/S0140-6736(21)01825-0. Epub 2021 Nov 17.
8
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.治疗性肝素与预防性肝素对中症 COVID-19 住院患者的死亡、机械通气或入住重症监护病房的影响：RAPID 随机临床试验。
BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400.
9
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.抗栓治疗对临床稳定有症状的 COVID-19 门诊患者临床结局的影响：ACTIV-4B 随机临床试验。
JAMA. 2021 Nov 2;326(17):1703-1712. doi: 10.1001/jama.2021.17272.
10
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性：HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.